LLYEli Lilly and CompanySigning up patients
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Carcinoma, Transitional Cell · Urinary Bladder Neoplasms · Neoplasm Metastasis
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 450 (planned)
- Started
- Dec 12, 2025
- Main results expected
- Oct 2029
- Fully finished
- May 2033
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants with treatment-related adverse events related to vepugratinib in combination with EV and pembrolizumab
Measured over: From baseline up to 90 months
Safety Lead-in: Overall Response Rate (ORR)
Measured over: From baseline up to 90 months
Progression-free Survival (PFS)
Measured over: Baseline to Study Completion (estimated as 6 years)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07218380 · record last updated 2026-10-07 · checked 2026-11-09 15:47 UTC